2-(2-methoxy-4-methylsulphinylphenyl)imidazo<1,2-a>pyrimidine | 93276-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-methoxy-4-methylsulphinylphenyl)imidazo<1,2-a>pyrimidine
• 英文别名: 2-(2-methoxy-4-methylsulfinylphenyl)imidazo[1,2-a]pyrimidine
• CAS: 93276-61-0
• 化学式: C₁₄H₁₃N₃O₂S
• 分子量: 287.342
• InChiKey: NVBGVCAKRWLWNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  75.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-甲氧基-4-(甲硫基)苯甲酰氯 在 正丁基锂 、 间氯过氧苯甲酸 、 copper(ll) bromide 作用下， 以 1,4-二氧六环 、 乙醇 、 氯仿 、 乙酸乙酯 为溶剂， 反应 14.5h， 生成 2-(2-methoxy-4-methylsulphinylphenyl)imidazo<1,2-a>pyrimidine
  参考文献：
  名称：

  Inotropic 2-arylimidazol[1,2-a]pyrimidines

  摘要：

  A series of 2-arylimidazo[1,2-a]pyrimidines has been prepared and evaluated for inotropic activity. Three of these heterocycles. ether 19, sulphide 21 and mesylate 24 displayed more potent inotropic effects in vitro than isomazole. The in vivo inotropic potencies of 4'-mesylate 24 and 4'-carboxamido analogue 23 were similar to those of isomazole and sulmazole respectively. The effects of some 'A' and 'C' ring substituents on the inotropic activities of the imidazo[1,2-a]pyrimidines were different from those on the imidazopyridines. Nevertheless the inotropic potencies of several imidazo[1.2-a]pyrimidines were closer to those of their 1H-imidazo[4,5-b]pyridine isomers than to those of the corresponding isomazole analogues. Structure-activity relationships are discussed in detail.

  DOI：

  10.1016/0223-5234(92)90004-k

文献信息

• Substituted imidazopyrimidines-pyrazines, and -triazines
  申请人：ELI LILLY AND COMPANY

  公开号：EP0113236A1

  公开（公告）日：1984-07-11

  Compounds having the formula (I) and their pharmaceutically acceptable salts, wherein one or two of A1, A2, A3, and A4 is N, and the remaining A1, A2, A3, and A4 are CH, provided that if A4 is N, then one of A1, A2, and A3 is also N, and provided that one of A1, A2, and A3 may be CX where X is halo; and each of R1, R2, and R3 is independently hydrogen, C1-C4 alkyl, C1-C4 alkoxy, allyloxy, benzyloxy, (C1-C4 alkyl) thio, (C1-C4 alkyl) sulfinyl, (C1-C4 alkyl)sulfonyl, hydroxy, halo, cyano, nitro, amino, mono- or di-(C1-C4 alkyl)amino, trifluoromethyl, or Z-Q-substituted C1-C4 alkoxy, wherein 0 is oxygen, sulfur, sulfinyl, sulfonyl, or a bond, and Z is C1-C4 alkyl, phenyl or phenyl substituted with halo, C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, amino, C1-C4 alkylthio, C,-C4 alkylsulfinyl, or C1-C4 alkylsulfonyl are ionotropic agents or intermediates thereto.

  具有式 (I) 的化合物 及其药学上可接受的盐类，其中 A1、A2、A3 和 A4 中的一个或两个是 N，其余的 A1、A2、A3 和 A4 是 CH，条件是如果 A4 是 N，则 A1、A2 和 A3 中的一个也是 N，并且 A1、A2 和 A3 中的一个可以是 CX，其中 X 是卤素；R1、R2 和 R3 各自独立地为氢、C1-C4 烷基、C1-C4 烷氧基、烯丙氧基、苄氧基、(C1-C4 烷基)硫基、(C1-C4 烷基)亚磺基、(C1-C4 烷基)磺酰基、羟基、卤代、氰基、硝基、氨基、单-或二-(C1-C4 烷基)氨基、三氟甲基或 Z-Q 取代的 C1-C4 烷氧基、其中 0 是氧、硫、亚砜基、磺酰基或键，Z 是 C1-C4 烷基、苯基或被卤素、C1-C4 烷基、C1-C4 烷氧基、羟基、硝基、氨基、C1-C4 烷硫基、C,-C4 烷基亚砜基或 C1-C4 烷基磺酰基取代的苯基。
• US4537889A
  申请人：——

  公开号：US4537889A

  公开（公告）日：1985-08-27
• US4636502A
  申请人：——

  公开号：US4636502A

  公开（公告）日：1987-01-13
• Inotropic 2-arylimidazol[1,2-a]pyrimidines
  作者：P Barraclough、JW Black、D Cambridge、E Capon、MR Cox、D Firmin、VP Gerskowitch、H Giles、RC Glen、AP Hill、RAD Hull、R Iyer、D Kettle、WR King、MS Nobbs、P Randall、P Skone、S Smith、SJ Vine、CJ Wharton、MV Whiting

  DOI：10.1016/0223-5234(92)90004-k

  日期：1992.4

  A series of 2-arylimidazo[1,2-a]pyrimidines has been prepared and evaluated for inotropic activity. Three of these heterocycles. ether 19, sulphide 21 and mesylate 24 displayed more potent inotropic effects in vitro than isomazole. The in vivo inotropic potencies of 4'-mesylate 24 and 4'-carboxamido analogue 23 were similar to those of isomazole and sulmazole respectively. The effects of some 'A' and 'C' ring substituents on the inotropic activities of the imidazo[1,2-a]pyrimidines were different from those on the imidazopyridines. Nevertheless the inotropic potencies of several imidazo[1.2-a]pyrimidines were closer to those of their 1H-imidazo[4,5-b]pyridine isomers than to those of the corresponding isomazole analogues. Structure-activity relationships are discussed in detail.